Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 19/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2677764 | 0.93 | ELANE (0.57) | ELANECYP3A4CYP2C9ADRB1HTR1A | |
| SCHEMBL2677656 | 0.90 | ELANE (0.55) | ELANECYP3A4CYP2C9 | |
| SCHEMBL4547784 | 0.90 | ELANE (0.60) | ELANECYP3A4CYP2C9ADRB1HTR1A | |
| SCHEMBL2678883 | 0.89 | ELANE (0.67) | ELANECYP3A4CYP2C9 | |
| SCHEMBL2678181 | 0.86 | ELANE (0.56) | ELANECYP3A4CYP2C9ADRB1HTR1A | |
| SCHEMBL4547793 | 0.85 | ELANE (0.60) | ELANECYP3A4CYP2C9 | |
| SCHEMBL4547796 | 0.85 | ELANE (0.56) | ELANECYP3A4CYP2C9 | |
| SCHEMBL4547775 | 0.85 | ELANE (0.56) | ELANECYP3A4CYP2C9ADRB1HTR1A | |
| SCHEMBL5668566 | 0.84 | ELANE (0.69) | ELANECYP3A4CYP2C9ADRB1HTR1A | |
| SCHEMBL4547790 | 0.83 | ELANE (0.53) | ELANECYP3A4CYP2C9ADRB1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173665-B2 | I-pheny 1-3,4-dihydropyrimidin-2(1H)-one derivatives and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-08 | — | — | US | disclosed |
| US-8173665-B2 | I-pheny 1-3,4-dihydropyrimidin-2(1H)-one derivatives and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-08 | — | — | US | disclosed |
| EP-1539710-B1 | HETEROCYCLIC DERIVATIVES | BAYER SCHERING PHARMA AG (DE) | 2010-10-27 | — | — | EP | disclosed |
| EP-1539710-B1 | HETEROCYCLIC DERIVATIVES | BAYER SCHERING PHARMA AG (DE) | 2010-10-27 | — | — | EP | disclosed |
| US-20100022537-A1 | I-PHENY 1-3,4-DIHYDROPYRIMIDIN-2(1H)-ONE DERIVATIVES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2010-01-28 | — | — | US | disclosed |
| US-20100022537-A1 | I-PHENY 1-3,4-DIHYDROPYRIMIDIN-2(1H)-ONE DERIVATIVES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2010-01-28 | — | — | US | disclosed |
| US-7566723-B2 | 1-phenyl1-3,4-dihydropyrimidin-2(1H)-one derivatives and their use | BAYER HEALTHCARE AG (DE) | 2009-07-28 | — | — | US | disclosed |
| US-7566723-B2 | 1-phenyl1-3,4-dihydropyrimidin-2(1H)-one derivatives and their use | BAYER HEALTHCARE AG (DE) | 2009-07-28 | — | — | US | disclosed |
| US-7566723-B2 | 1-phenyl1-3,4-dihydropyrimidin-2(1H)-one derivatives and their use | BAYER HEALTHCARE AG (DE) | 2009-07-28 | — | — | US | disclosed |
| US-20060111377-A1 | Heterocyclic derivatives | BAYER HEALTHCARE A G (DE) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022537-A1 | I-PHENY 1-3,4-DIHYDROPYRIMIDIN-2(1H)-ONE DERIVATIVES AND THEIR USE | TNNI3, HIF1AN, TNNT2 | ELANE 314/4885CYP3A4 1262/4885CYP2C9 1933/4885 |
| US-20060111377-A1 | Heterocyclic derivatives | TNNI3, TBXA2R, TNNT2 | ELANE 137/4885CYP3A4 651/4885CYP2C9 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.